Tradename | Company | Number | Date | Products |
---|---|---|---|---|
TAVNEOS | Chemocentryx | N-214487 RX | 2021-10-07 | 1 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
tavneos | New Drug Application | 2024-12-10 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
anti-neutrophil cytoplasmic antibody-associated vasculitis | — | D056648 | I77.82 |
Expiration | Code | ||
---|---|---|---|
AVACOPAN, TAVNEOS, CHEMOCENTRYX | |||
2028-10-07 | ODE-377 | ||
2026-10-07 | NCE |
Drug common name | Avacopan |
INN | avacopan |
Description | Avacopan, sold under the brand name Tavneos, is a medication used to treat anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Avacopan is a complement 5a receptor antagonist and a cytochrome P450 3A4 inhibitor.
|
Classification | Small molecule |
Drug class | complement receptor antagonists/complement inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(NC(=O)[C@H]2CCCN(C(=O)c3c(C)cccc3F)[C@H]2c2ccc(NC3CCCC3)cc2)cc1C(F)(F)F |
PDB | — |
CAS-ID | 1346623-17-3 |
RxCUI | — |
ChEMBL ID | CHEMBL3989871 |
ChEBI ID | — |
PubChem CID | 49841217 |
DrugBank | DB15011 |
UNII ID | O880NM097T (ChemIDplus, GSRS) |